BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 3923849)

  • 1. Benefits, risks and costs of immunization for measles, mumps and rubella.
    White CC; Koplan JP; Orenstein WA
    Am J Public Health; 1985 Jul; 75(7):739-44. PubMed ID: 3923849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
    Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
    Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
    J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A benefit-cost analysis of two-dose measles immunization in Canada.
    Pelletier L; Chung P; Duclos P; Manga P; Scott J
    Vaccine; 1998; 16(9-10):989-96. PubMed ID: 9682349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Economic evaluation on different two-dose-vaccination-strategies related to Measles, Mumps and Rubella Combined Attenuated Live Vaccine].
    He HQ; Zhang B; Yan R; Li Q; Fu J; Tang XW; Zhou Y; Deng X; Xie SY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Aug; 37(8):1121-6. PubMed ID: 27539345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [35-year measles, mumps, rubella vaccination assessment in France].
    Reinert P; Soubeyrand B; Gauchoux R
    Arch Pediatr; 2003 Nov; 10(11):948-54. PubMed ID: 14613687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
    Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
    N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The virtual elimination of rubella and mumps from the United States and the use of combined measles, mumps and rubella vaccines (MMR) to eliminate measles.
    Bart KJ; Orenstein WA; Hinman AR
    Dev Biol Stand; 1986; 65():45-52. PubMed ID: 3104117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measles, mumps and rubella: control by vaccination.
    van Druten JA; de Boo T; Plantinga AD
    Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Watson JC; Hadler SC; Dykewicz CA; Reef S; Phillips L
    MMWR Recomm Rep; 1998 May; 47(RR-8):1-57. PubMed ID: 9639369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Certain problems with limits of immunity against measles, mumps and rubella].
    Magdzik W
    Przegl Epidemiol; 1993; 47(1-2):47-53. PubMed ID: 8351387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Health and economic benefits of mandatory regular vaccination in Slovakia. IV. Measles, rubella and mumps].
    Hudecková H; Straka S; Avdicová M; Rusnáková S
    Epidemiol Mikrobiol Imunol; 2001 Feb; 50(1):31-5. PubMed ID: 11233671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases.
    Thompson KM; Badizadegan ND
    Risk Anal; 2017 Jun; 37(6):1109-1131. PubMed ID: 28561947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Elimination of measles, mumps and rubella in Switzerland].
    Herzog C
    Soz Praventivmed; 1986; 31(6):326-9. PubMed ID: 3811611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
    Heath TC; Burgess MA; O'Brien ED
    Commun Dis Intell; 1998 Aug; 22(8):159. PubMed ID: 9735551
    [No Abstract]   [Full Text] [Related]  

  • 18. Mumps incidence in Israel--impact of MMR vaccine.
    Slater PE; Roitman M; Costin C
    Public Health Rev; 1990-1991; 18(1):88-93. PubMed ID: 2132885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanded programme on immunization. Immunization coverage against measles, mumps and rubella.
    Wkly Epidemiol Rec; 1993 Mar; 68(12):83-6. PubMed ID: 8452784
    [No Abstract]   [Full Text] [Related]  

  • 20. Rates of first measles-mumps-rubella immunisation in Wales (UK).
    Thomas DR; Salmon RL; King J
    Lancet; 1998 Jun; 351(9120):1927. PubMed ID: 9654262
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.